prr's cvac - one billion dollars per year?

Well, that's what the following article from Bloomberg states with reference to Merck's attempt:

http://www.bloomberg.com/news/2012-12-19/merck-kgaa-lung-cancer-drug-misses-trial-s-survival-goal.html

...'the company’s ambitions of turning the medicine into a $1 billion-a-year-product.'

If Prima Biomed's Cvac can be used upon several cancers are we looking at more than One Billion dollars per year year in commercial revenue for Prima Biomed?

Analyst's Reports and their Price Targets of around 30 cents maybe undervaluing this company by a factor of 5.

But, wait-a-minute, where's PRR's stock price today - 11.5 cents?

Well, let's make that a factor of at least x 12 times against today's price!

2014 is coming, sooner or later the market will suddenly snap-to-attention upon the realisation of the tremendous commercial revenue earning potential of this great little company.

Great Article
http://www.dailyfinance.com/2010/10/06/inside-wall-street-is-this-tiny-aussie-biotech-the-next-dendreo/

PRR’s technology and process is not like Merck / Oncothyreon / Stimuvax, instead it is similar to Dendreon’s process for its cancer immunotherapy 'Provenge,' - which has ALREADY been APPROVED.